Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-03-19Clinical Trial Update: Brivanib Metastatic Renal Cell Carcinoma [Phase 2]
Phase 2 trial update for brivanib in metastatic renal cell carcinoma; study terminated with results posted.
-
FDA approval · 2021-03-10FDA Approved: FOTIVDA — Original Application (AVEO Pharmaceuticals, Inc.)
FDA approved Fotivda (tivozanib) as the original US approval for adults with relapsed or refractory renal cell carcinoma following one prior…
-
CLINICAL_TRIALS trial_result · 2021-03-05Clinical Trial Update: Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma [Phase 2]
Phase 2 study evaluating safety and efficacy of lenvatinib (18 mg vs 14 mg) in combination with everolimus for renal cell carcinoma has comp…
-
CLINICAL_TRIALS trial_result · 2021-02-24Clinical Trial Update: Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma [Phase 2]
Phase 2 biomarker trial of everolimus in advanced renal cell carcinoma has completed; results posted.
-
CLINICAL_TRIALS trial_result · 2021-02-24Clinical Trial Update: Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer [Phase 1, Phase 2]
Phase 1/2 trial of entinostat in combination with aldesleukin for renal cell carcinoma, with results posted and the study listed as active/n…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma [Phase 2]
Phase 2 trial comparing MLN0128 (and MLN0128 + MLN1117) vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma;…
-
FDA approval · 2021-02-11FDA Approved: EVEROLIMUS — Original Application (NorthStar RxLLC)
FDA approved NorthStar RxLLC's original application (ANDA) for Everolimus, a generic version of the mTOR inhibitor. The approval enables a g…
-
CLINICAL_TRIALS trial_result · 2021-02-08Clinical Trial Update: CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma [Phase 3]
A Phase 3 trial evaluating CM082 in combination with everolimus in Chinese patients with metastatic renal cell carcinoma is currently status…
-
CLINICAL_TRIALS trial_result · 2021-01-26Clinical Trial Update: Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma [Phase 1, Phase 2]
A Phase 1/2 trial studying vandetanib combined with metformin in patients with hereditary leiomyomatosis-related renal cell carcinoma (HLRCC…
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors [Phase 2]
Phase 2 trial assessing efficacy and safety of LDP in patients with bladder cancer, renal carcinoma, and advanced penile carcinoma.
-
CLINICAL_TRIALS trial_result · 2021-01-19Clinical Trial Update: Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma [Phase 2]
Phase 2 trial evaluating cabozantinib as subsequent therapy after an immune checkpoint-based treatment in renal cell carcinoma is underway, …
-
CLINICAL_TRIALS trial_result · 2021-01-06Clinical Trial Update: Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial update evaluating avelumab plus intermittent axitinib in previously untreated metastatic renal cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. [Phase 2]
Phase 2 trial update evaluating nivolumab and ipilimumab in patients with T1aN0M0 renal cell carcinoma ineligible for surgery.
-
CLINICAL_TRIALS trial_result · 2020-12-19Clinical Trial Update: A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer [Phase 1, Phase 2]
Phase 1/2 study evaluating emibetuzumab in combination with ramucirumab in various advanced cancers, with completed status and results poste…
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing [Phase 2]
Phase 2 trial evaluating an alternative dosing schedule of sunitinib in metastatic renal cell carcinoma, using cardiopulmonary exercise test…
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma [Phase 2]
Phase 2 trial evaluating an individualized treatment strategy for patients with metastatic non-clear cell renal cell carcinoma is ongoing, s…
-
CLINICAL_TRIALS trial_result · 2020-11-23Clinical Trial Update: A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) [Phase 3]
Phase 3 trial evaluating pazopanib as adjuvant treatment for localized renal cell carcinoma has completed (results posted in 2020).
-
CLINICAL_TRIALS trial_result · 2020-11-13Clinical Trial Update: Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. [Phase 2]
Phase 2 trial evaluating sunitinib in first-line renal cell carcinoma after progression on immunotherapy has completed.
-
FDA approval · 2020-11-12FDA Approved: SORAFENIB — Original Application (Teva Pharmaceuticals, Inc.)
The FDA approved Teva's original application for a generic sorafenib product, enabling a generic version of the cancer drug Sorafenib to be …
-
CLINICAL_TRIALS trial_result · 2020-10-27Clinical Trial Update: A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma [Phase 2]
Phase 2 biomarker study of tivozanib in advanced renal cell carcinoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-10-27Clinical Trial Update: A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC [Phase 2]
Phase 2 trial comparing tivozanib versus sunitinib in metastatic renal cell carcinoma has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer [Phase 2]
Phase 2 trial update for TroVax vaccine with IL-2 in stage IV renal cell carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma [Phase 2]
Phase 2 trial update on TroVax vaccine with IL-2 in renal cell carcinoma assessing safety and biological activity.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma [Phase 1, Phase 2]
A randomized Phase 2 trial evaluating axitinib with TRC105 versus axitinib alone in renal cell carcinoma was terminated; results posted in 2…
-
CLINICAL_TRIALS trial_result · 2020-10-05Clinical Trial Update: An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). [Phase 3]
Extension treatment protocol for participants from a Phase 3 trial comparing tivozanib vs sorafenib in advanced renal cell carcinoma.